Scleroderma, Diffuse: Clinical Trials

11 trials for Scleroderma, Diffuse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 recruiting. 11 Phase 1, 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Recruiting 11
Phase 25Recruiting 5

Follow Scleroderma, Diffuse: new trials by email Literature Review of Scleroderma, Diffuse trials Research Report on Scleroderma, Diffuse

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
US Zamto-cel Autoimmune Diseases
zamtocabtagene autoleucel, Cyclophosphamide, Fludarabine - Lupus Nephritis, Systemic Lupus Erythematosus
Phase 1RecruitingMiltenyi Biomedicine GmbH482026-07-012026-06-11
Controlling Hyperactive Immunity With Long-lived Lymphocytes
QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA)
Phase 1 / Phase 2RecruitingQuell Therapeutics Limited162026-04-102026-10-19
A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases
XmAb657 - Healthy, Idiopathic Inflammatory Myopathies
Phase 1RecruitingXencor, Inc.602026-02-242026-08-03
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
ALLO-329, Cyclophosphamide, Fludarabine - Systemic Lupus Erythematosus (With and Without Nephritis), Idiopathic Inflammatory Myopathy
Phase 1RecruitingAllogene Therapeutics662025-11-132026-11-02
A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.
PRO-203, Placebo - Healthy Volunteers, Systemic Sclerosis (SSc)
Phase 1 / Phase 2RecruitingProlium Bioscience, Inc442025-10-272026-10-09
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
BMS-986515, Fludarabine, Cyclophosphamide - Refractory Autoimmune Diseases
Phase 1RecruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company1252025-09-042026-07-14
Efficacy and Safety of HN2301 in Autoimmune Diseases(AIDs)
HN2301 injection - Systemic Lupus Erythematosus, Scleroderma
Phase 1RecruitingShenzhen MagicRNA Biotechnology Co., Ltd302025-03-162026-08-12
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
CTX112 - SLE (Systemic Lupus), Lupus Erythematosus, Systemic
Phase 1RecruitingCRISPR Therapeutics802025-03-102026-10-26
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis
Phase 1 / Phase 2RecruitingFondazione Policlinico Universitario Agostino Gemelli IRCCS82024-11-292025-04-11
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NKX019, Fludarabine, Cyclophosphamide - Systemic Sclerosis, Idiopathic Inflammatory Myopathies
Phase 1 / Phase 2RecruitingNkarta, Inc.2402024-11-042026-10-30
Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis
Mesenchymal stromal cells, Placebo - Systemic Sclerosis, Digital Ulcer
Phase 1 / Phase 2RecruitingUMC Utrecht202021-10-062025-09-10

Narrower conditions

Scleroderma, Systemic (9)  ·  Lupus Erythematosus, Systemic (6)  ·  Myositis (5)  ·  Arthritis, Rheumatoid (4)  ·  Autoimmune Diseases (4)  ·  Lupus Nephritis (4)  ·  Dermatomyositis (3)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (2)  ·  Polymyositis (2)  ·  Connective Tissue Diseases (1)  ·  Immune System Diseases (1)  ·  Muscular Diseases (1)  ·  Musculoskeletal Diseases (1)  ·  Sclerosis (1)

Broader conditions

Skin and Connective Tissue Diseases (11)  ·  Connective Tissue Diseases (10)  ·  Skin Diseases (10)  ·  Immune System Diseases (8)  ·  Musculoskeletal Diseases (7)  ·  Nervous System Diseases (6)  ·  Neuromuscular Diseases (6)  ·  Arthritis (5)  ·  Autoimmune Diseases (5)  ·  Joint Diseases (5)  ·  Muscular Diseases (5)  ·  Rheumatic Diseases (5)  ·  Female Urogenital Diseases (4)  ·  Female Urogenital Diseases and Pregnancy Complications (4)  ·  Glomerulonephritis (4)

Interventions

Cyclophosphamide (4)  ·  fludarabine (4)  ·  Immunotherapy, Adoptive (1)  ·  tocilizumab (1)

Sponsors

Allogene Therapeutics (1)  ·  CRISPR Therapeutics (1)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)  ·  Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1)  ·  Miltenyi Biomedicine GmbH (1)  ·  Nkarta, Inc. (1)  ·  Prolium Bioscience, Inc (1)  ·  Quell Therapeutics Limited (1)  ·  Shenzhen MagicRNA Biotechnology Co., Ltd (1)  ·  UMC Utrecht (1)  ·  Xencor, Inc. (1)

Countries

United States (5)  ·  Australia (3)  ·  Germany (3)  ·  Spain (3)  ·  China (2)  ·  Brazil (1)  ·  Canada (1)  ·  Czechia (1)  ·  France (1)  ·  Israel (1)  ·  Italy (1)  ·  Mexico (1)  ·  Netherlands (1)  ·  Poland (1)  ·  Romania (1)

Top investigators

Esther Eromosele, MD (1)  ·  Maria Antonietta D'Agostino (1)  ·  Marianne Verhaar, MD, PhD (1)  ·  Salim Mujais (1)  ·  Zhu Chen, MD (1)

Results publications

PMID 30127049

NIH funding

2015 (1), 2025 (1)